Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × Metastatic Hormone Sensitive Prostate Cancer × Androgen Antagonists × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 19 Neoplasm Metastasis 2 Urogenital Neoplasms 1 Stage IV Prostate Adenocarcinoma AJCC v7 1 Radiation Injuries 1 Prostatic Diseases 1 Prostate Adenocarcinoma 1 PSA Level Greater Than 0.03 1 Neoplasms 1 Metastatic Hormone Sensitive Prostate Cancer 1 Metastatic Castrate-sensitive Prostate Cancer 1 Hormone Sensitive Prostate Cancer 1 Genital Neoplasms, Male 1

Interventions

enzalutamide 1 Androgen Antagonists 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04076059 2026-02-06

China ARCHES

Astellas Pharma Inc

Phase 3 Active not recruiting

180 enrolled 24 charts

Metastatic Hormone Sensitive Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡